MorphoSys AG — Regulatory Filings 2002

Feb 25, 2002

News Details

Ad-hoc | 25 February 2002 07:46

MorphoSys AG english

MORPHOSYS AND XOMA CROSS-LICENSE ANTIBODY TECHNOLOGIES Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MORPHOSYS AND XOMA CROSS-LICENSE ANTIBODY TECHNOLOGIES MorphoSys Sole Licensee of XOMA Technology among Antibody Library Companies MorphoSys AG (Neuer Markt: MOR) and XOMA Ltd. (Nasdaq: XOMA) announced today they have entered into cross-licensing agreements for antibody-related technologies. Under the agreements, MorphoSys and its partners receive a license to use the XOMA antibody expression technology for developing antibody products (including Fab and scFv formats) using MorphoSys’ phage display-based HuCAL antibody library. MorphoSys also receives a license for the production of antibodies (including Fab and scFv formats) under the XOMA patents. XOMA will receive license payments from MorphoSys in addition to a license to use the MorphoSys HuCAL GOLD antibody library for its target discovery and research programs. The agreements also provide for a release of MorphoSys and its collaborators from any past activities using MorphoSys technology to the extent they also used XOMA’s antibody expression technology, and allows MorphoSys to use the XOMA technology in combination with its own technology in any future collaborations. XOMA will receive the right to use the HuCAL GOLD antibody library for target research and discovery purposes for five years, with an option to develop antibodies into therapeutics. Should any therapeutic antibodies be identified and developed by XOMA using the MorphoSys HuCAL GOLD library, the contract provides for future license, milestone and royalty payments be made by XOMA to MorphoSys. end of ad-hoc-announcement (c)DGAP 25.02.2002 ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 250746 Feb 02